The role of natural killer cells in autoimmune liver disease: A comprehensive review

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 55-65

  Hudspeth, Kelly ^a   Pontarini, Elena ^a   Tentorio, Paolo ^a   Cimino, Matteo ^a   Donadon, Matteo ^a   Torzilli, Guido ^a,b   Lugli, Enrico ^a   Della Bella, Silvia ^a   Gershwin, M Eric ^c   Mavilio, Domenico ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune hepatitis; Hepatic natural killer cell subsets; Primary biliary cirrhosis; Primary sclerosing cholangitis; Tolerance

Indexed keywords

ANTINUCLEAR ANTIBODY; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; NATURAL KILLER CELL RECEPTOR; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY;

AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; GENDER; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; MURINE MODEL; NATURAL KILLER CELL; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW;

AUTOIMMUNE HEPATITIS; HEPATIC NATURAL KILLER CELL SUBSETS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; TOLERANCE;

ANIMALS; AUTOIMMUNE DISEASES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LIVER DISEASES; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, NATURAL KILLER CELL;

EID: 84886294585     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.07.003     Document Type: Review

References (134)

1. Shi F.D., Ljunggren H.G., La Cava A., Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011, 11:658-671.
2. Lotze Michael T., Thomson A.W. Natural killer cells-basic science and clinical application 2010, Elsevier.
3. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
4. Schleinitz N., Vely F., Harle J.R., Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010, 131:451-458.
5. Khakoo S.I., Carrington M. KIR and disease: a model system or system of models?. Immunol Rev 2006, 214:186-201.
6. Jie H.B., Sarvetnick N. The role of NK cells and NK cell receptors in autoimmune disease. Autoimmunity 2004, 37:147-153.
7. Johansson S., Berg L., Hall H., Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol 2005, 26:613-618.
8. Flodstrom-Tullberg M., Bryceson Y.T., Shi F.D., Hoglund P., Ljunggren H.G. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009, 21:634-640.
9. Kaneda K., Kurioka N., Seki S., Wake K., Yamamoto S. Pit cell-hepatocyte contact in autoimmune hepatitis. Hepatology 1984, 4:955-958.
10. Knolle P.A. Role and function of liver sinusoidal endothelial cells. Liver immunology: principle and practice 2007, 25-39. Humana Press, Totowa, New Jersey. M.E. Gershwin, J.M. Vierling, M.P. Manns (Eds.).
11. Golo Ahlenstiel B.R. Hepatic NK, NKT, and T Cells. Liver immunology: principle and practice 2007, 71-82. Humana Press, Totowa, New Jersey. M.E. Gershwin, J.M. Vierling, M.P. Manns (Eds.).
12. O'Farrelly Cliona, Innate immune mechanisms in the liver. Liver immunology: principle and articles 2007, 41-48. Humana Press, Totowa, New Jersey. M.E. Gershwin, J.M. Vierling, M.P. Manns (Eds.).
13. Knolle P., Lohr H., Treichel U., Dienes H.P., Lohse A., Schlaack J., et al. Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. ZGastroenterol 1995, 33:613-620.
14. Knolle P., Schlaak J., Uhrig A., Kempf P., Meyer zum Buschenfelde K.H., Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. JHepatol 1995, 22:226-229.
15. Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. JExp Med 1995, 181:1887-1892.
16. Gershwin M.Eric, Vierling J.M., Manns Michael P. Liver immunology: principle and articles 2007, Humana Press, Totowa, New Jersey.
17. Krawitt E.L. Autoimmune hepatitis. NEngl J Med 1996, 334:897-903.
18. Gossard A.A., Lindor K.D. Autoimmune hepatitis: a review. JGastroenterol 2012, 47:498-503.
19. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. JHepatol 1999, 31:929-938.
20. Teufel A., Weinmann A., Kahaly G.J., Centner C., Piendl A., Worns M., et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. JClin Gastroenterol 2010, 44:208-213.
21. Bittencourt P.L., Farias A.Q., Porta G., Cancado E.L., Miura I., Pugliese R., et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. JClin Gastroenterol 2008, 42:300-305.
22. Czaja A.J., Strettell M.D., Thomson L.J., Santrach P.J., Moore S.B., Donaldson P.T., et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997, 25:317-323.
23. Oo Y.H., Hubscher S.G., Adams D.H. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 2010, 4:475-493.
24. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. NEngl J Med 2005, 353:1261-1273.
25. Smyk D.S., Rigopoulou E.I., Pares A., Billinis C., Burroughs A.K., Muratori L., et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol 2012, 2012:610504.
26. Longhi M.S., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. JHepatol 2004, 41:31-37.
27. Kita H., Lian Z.X., Van de Water J., He X.S., Matsumura S., Kaplan M., et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. JExp Med 2002, 195:113-123.
28. Talwalkar J.A., Lindor K.D. Primary biliary cirrhosis. Lancet 2003, 362:53-61.
29. Shimoda S., Selmi C., Gershwin M.E. Fractalkine and other chemokines in primary biliary cirrhosis. Int J Hepatol 2012, 2012:102839.
30. Harada K., Van de Water J., Leung P.S., Coppel R.L., Ansari A., Nakanuma Y., et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997, 25:791-796.
31. Harada K., Shimoda S., Sato Y., Isse K., Ikeda H., Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009, 157:261-270.
32. Ludwig J., MacCarty R.L., LaRusso N.F., Krom R.A., Wiesner R.H. Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis. Hepatology 1986, 6:560-568.
33. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
34. Escorsell A., Pares A., Rodes J., Solis-Herruzo J.A., Miras M., de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish association for the study of the liver. JHepatol 1994, 21:787-791.
35. Broome U., Olsson R., Loof L., Bodemar G., Hultcrantz R., Danielsson A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
36. Karlsen T.H., Franke A., Melum E., Kaser A., Hov J.R., Balschun T., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
37. Hov J.R., Boberg K.M., Karlsen T.H. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008, 14:3781-3791.
38. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
39. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
40. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-648.
41. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
42. Long E.O. Versatile signaling through NKG2D. Nat Immunol 2002, 3:1119-1120.
43. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
44. Smyth M.J., Godfrey D.I., Trapani J.A. Afresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2:293-299.
45. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
46. Fauci A.S., Mavilio D., Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005, 5:835-843.
47. Gupta N., Arthos J., Khazanie P., Steenbeke T.D., Censoplano N.M., Chung E.A., et al. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 2005, 332:491-497.
48. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001, 1:41-49.
49. Hudspeth K., Fogli M., Correia D.V., Mikulak J., Roberto A., Della Bella S., et al. Engagement of NKp30 on Vdelta1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood 2012, 119:4013-4016.
50. Brunetta E., Fogli M., Varchetta S., Bozzo L., Hudspeth K.L., Marcenaro E., et al. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 2010, 24:27-34.
51. Brunetta E., Hudspeth K.L., Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. JLeukoc Biol 2010, 88:1119-1130.
52. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5:112-124.
53. Walzer T., Dalod M., Robbins S.H., Zitvogel L., Vivier E. Natural killer cells and dendritic cells: "l'union fait la force". Blood 2005, 106:2252-2258.
54. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. JExp Med 2002, 195:F9-F14.
55. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002, 2:957-964.
56. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., Caligiuri M.A. NK cell and DC interactions. Trends Immunol 2004, 25:47-52.
57. Mavilio D., Lombardo G., Kinter A., Fogli M., La Sala A., Ortolano S., et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. JExp Med 2006, 203:2339-2350.
58. Bellora F., Castriconi R., Dondero A., Reggiardo G., Moretta L., Mantovani A., et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A 2010, 107:21659-21664.
59. Nedvetzki S., Sowinski S., Eagle R.A., Harris J., Vely F., Pende D., et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007, 109:3776-3785.
60. Michel T., Hentges F., Zimmer J. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front Immunol 2012, 3:403.
61. Costantini C., Calzetti F., Perbellini O., Micheletti A., Scarponi C., Lonardi S., et al. Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFN{gamma}: role of CD18, ICAM-1, and ICAM-3. Blood 2011, 117:1677-1686.
62. Doherty D.G., Norris S., Madrigal-Estebas L., McEntee G., Traynor O., Hegarty J.E., et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. JImmunol 1999, 163:2314-2321.
63. Vermijlen D., Luo D., Froelich C.J., Medema J.P., Kummer J.A., Willems E., et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. JLeukoc Biol 2002, 72:668-676.
64. Vanderkerken K., Bouwens L., Wisse E. Characterization of a phenotypically and functionally distinct subset of large granular lymphocytes (pit cells) in rat liver sinusoids. Hepatology 1990, 12:70-75.
65. Bouwens L., Jacobs R., Remels L., Wisse E. Natural cytotoxicity of rat hepatic natural killer cells and macrophages against a syngeneic colon adenocarcinoma. Cancer Immunol Immunotherapy: CII 1988, 27:137-141.
66. Luo D., Vanderkerken K., Bouwens L., Kuppen P.J., Baekeland M., Seynaeve C., et al. The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver. Hepatology 1996, 24:1475-1480.
67. Luo D., Vermijlen D., Vanderkerken K., Kuppen P.J., Seynaeve C., Eddouks M., et al. Involvement of LFA-1 in hepatic NK cell (pit cell)-mediated cytolysis and apoptosis of colon carcinoma cells. JHepatol 1999, 31:110-116.
68. Vermijlen D., Seynaeve C., Luo D., Kruhoffer M., Eizirik D.L., Orntoft T.F., et al. High-density oligonucleotide array analysis reveals extensive differences between freshly isolated blood and hepatic natural killer cells. Eur J Immunol 2004, 34:2529-2540.
69. Ishiyama K., Ohdan H., Ohira M., Mitsuta H., Arihiro K., Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006, 43:362-372.
70. Stegmann K.A., Bjorkstrom N.K., Veber H., Ciesek S., Riese P., Wiegand J., et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010, 138:1885-1897.
71. Takeda K., Okumura K. Current advances and expectations in tumor immunology. Hum Cell 2001, 14:159-163.
72. Jeong W.I., Park O., Radaeva S., Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006, 44:1441-1451.
73. Gao B., Radaeva S., Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. JLeukoc Biol 2009, 86:513-528.
74. Passweg J.R., Huard B., Tiercy J.M., Roosnek E. HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 2007, 28:437-441.
75. Daar A.S., Fuggle S.V., Fabre J.W., Ting A., Morris P.J. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984, 38:293-298.
76. Eisenberger C.F., Viebahn R., Lauchart W., de Groot H., Becker H.D. MHC antigen presentation on the surface of hepatocytes: modulation during and after hypoxic stress. Transpl Int 1994, 7(Suppl.1):S163-S166.
77. Gugenheim J., Baldini E., Ouzan D., Mazza D., Saint-Paul M.C., Goubaux B., et al. Course of the recurrence of hepatitis C virus infection after liver transplantation. Gastroenterol Clin Biol 1996, 20:730-735.
78. So S.K., Platt J.L., Ascher N.L., Snover D.C. Increased expression of class I major histocompatibility complex antigens on hepatocytes in rejecting human liver allografts. Transplantation 1987, 43:79-85.
79. Lau J.Y., Wright T.L. Molecular virology and pathogenesis of hepatitis B. Lancet 1993, 342:1335-1340.
80. Franco A., Barnaba V., Natali P., Balsano C., Musca A., Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988, 8:449-454.
81. Salazar-Mather T.P., Orange J.S., Biron C.A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. JExp Med 1998, 187:1-14.
82. Liu Z.X., Govindarajan S., Okamoto S., Dennert G. Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. Hepatology 2000, 31:665-673.
83. Zou Y., Chen T., Han M., Wang H., Yan W., Song G., et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. JImmunol 2010, 184:466-475.
84. Ochi M., Ohdan H., Mitsuta H., Onoe T., Tokita D., Hara H., et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004, 39:1321-1331.
85. Takeda K., Cretney E., Hayakawa Y., Ota T., Akiba H., Ogasawara K., et al. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 2005, 105:2082-2089.
86. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
87. Leifeld L., Cheng S., Ramakers J., Dumoulin F.L., Trautwein C., Sauerbruch T., et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002, 36:1001-1008.
88. Hussain M.J., Mustafa A., Gallati H., Mowat A.P., Mieli-Vergani G., Vergani D. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. JHepatol 1994, 21:816-821.
89. Czaja A.J. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001, 96:1224-1231.
90. Jinushi M., Takehara T., Tatsumi T., Kanto T., Miyagi T., Suzuki T., et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. JImmunol 2004, 173:6072-6081.
91. Varchetta S., Mele D., Mantovani S., Oliviero B., Cremonesi E., Ludovisi S., et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012, 56:841-849.
92. Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N., et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology 2007, 120:73-82.
93. Lassen M.G., Lukens J.R., Dolina J.S., Brown M.G., Hahn Y.S. Intrahepatic IL-10 maintains NKG2A+Ly49- liver NK cells in a functionally hyporesponsive state. JImmunol 2010, 184:2693-2701.
94. Tu Z., Bozorgzadeh A., Pierce R.H., Kurtis J., Crispe I.N., Orloff M.S. TLR-dependent cross talk between human Kupffer cells and NK cells. JExp Med 2008, 205:233-244.
95. O'Leary J.G., Goodarzi M., Drayton D.L., von Andrian U.H. Tcell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006, 7:507-516.
96. Paust S., Gill H.S., Wang B.Z., Flynn M.P., Moseman E.A., Senman B., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010, 11:1127-1135.
97. Pillarisetty V.G., Katz S.C., Bleier J.I., Shah A.B., Dematteo R.P. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. JImmunol 2005, 174:2612-2618.
98. Crispe I.N. Liver antigen-presenting cells. JHepatol 2011, 54:357-365.
99. Nagler A., Lanier L.L., Cwirla S., Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. JImmunol 1989, 143:3183-3191.
100. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
101. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. JExp Med 1990, 171:1509-1526.
102. Arase H., Saito T., Phillips J.H., Lanier L.L. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). JImmunol 2001, 167:1141-1144.
103. Koo G.C., Peppard J.R., Mark W.H. Natural killer cells generated from bone marrow culture. JImmunol 1984, 132:2300-2304.
104. Mavilio D., Benjamin J., Kim D., Lombardo G., Daucher M., Kinter A., et al. Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood 2005, 106:1718-1725.
105. Walzer T., Blery M., Chaix J., Fuseri N., Chasson L., Robbins S.H., et al. Identification, activation, and selective invivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A 2007, 104:3384-3389.
106. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23.
107. Vivier E., Spits H., Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair?. Nat Rev Immunol 2009, 9:229-234.
108. Jabri B., de Serre N.P., Cellier C., Evans K., Gache C., Carvalho C., et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000, 118:867-879.
109. Yu J., Mitsui T., Wei M., Mao H., Butchar J.P., Shah M.V., et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. JClin Invest 2011, 121:1456-1470.
110. Strassburg C.P., Obermayer-Straub P., Manns M.P. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000, 18:127-139.
111. Chen Y., Wei H., Gao B., Hu Z., Zheng S., Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. JViral Hepat 2005, 12:38-45.
112. Gershwin M.E., Ansari A.A., Mackay I.R., Nakanuma Y., Nishio A., Rowley M.J., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000, 174:210-225.
113. Lleo A., Bowlus C.L., Yang G.X., Invernizzi P., Podda M., Van de Water J., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010, 52:987-998.
114. Chuang Y.H., Lian Z.X., Tsuneyama K., Chiang B.L., Ansari A.A., Coppel R.L., et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. JAutoimmun 2006, 26:232-240.
115. Maghazachi A.A. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 2010, 341:37-58.
116. Shimoda S., Harada K., Niiro H., Shirabe K., Taketomi A., Maehara Y., et al. Interaction between toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011, 53:1270-1281.
117. Gao B., Bertola A. Natural killer cells take two tolls to destruct bile ducts. Hepatology 2011, 53:1076-1079.
118. Chuang Y.H., Lian Z.X., Cheng C.M., Lan R.Y., Yang G.X., Moritoki Y., et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. JAutoimmun 2005, 25:126-132.
119. Isse K., Harada K., Zen Y., Kamihira T., Shimoda S., Harada M., et al. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005, 41:506-516.
120. Liang Y., Yang Z., Li C., Zhu Y., Zhang L., Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin Exp Med 2008, 8:1-7.
121. Takeda K., Kojima Y., Ikejima K., Harada K., Yamashina S., Okumura K., et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008, 105:10895-10900.
122. Bergquist A., Lindberg G., Saarinen S., Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. JHepatol 2005, 42:252-256.
123. Karlsen T.H., Boberg K.M., Olsson M., Sun J.Y., Senitzer D., Bergquist A., et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. JHepatol 2007, 46:899-906.
124. Steinle A., Li P., Morris D.L., Groh V., Lanier L.L., Strong R.K., et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001, 53:279-287.
125. Van Steenbergen W., De Goede E., Emonds M.P., Reinders J., Tilanus M., Fevery J. Primary sclerosing cholangitis in two brothers: report of a family with special emphasis on molecular HLA and MICA genotyping. Eur J Gastroenterol Hepatol 2005, 17:767-771.
126. Donaldson P.T., Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002, 35:555-564.
127. Wiencke K., Spurkland A., Schrumpf E., Boberg K.M. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001, 34:625-630.
128. Norris S., Kondeatis E., Collins R., Satsangi J., Clare M., Chapman R., et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001, 120:1475-1482.
129. Melum E., Karlsen T.H., Schrumpf E., Bergquist A., Thorsby E., Boberg K.M., et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008, 47:90-96.
130. Karlsen T.H., Schrumpf E., Boberg K.M. Update on primary sclerosing cholangitis. Dig Liver Dis 2010, 42:390-400.
131. Panasiuk A., Prokopowicz D., Zak J., Panasiuk B., Wysocka J. Lymphocyte subpopulations in peripheral blood in primary sclerosing cholangitis. Hepatogastroenterology 2004, 51:1289-1291.
132. Silvain C., Zeevi A., Saidman S., Duquesnoy R.J., Van Thiel D.H. Phenotypic and functional characteristics of colonic lymphocytes isolated from patients with primary sclerosing cholangitis and inflammatory bowel disease. Hepatogastroenterology 1995, 42:250-258.
133. Hata K., Zhang X.R., Iwatsuki S., Van Thiel D.H., Herberman R.B., Whiteside T.L. Isolation, phenotyping, and functional analysis of lymphocytes from human liver. Clin Immunol Immunopathol 1990, 56:401-419.
134. Bo X., Broome U., Remberger M., Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001, 49:131-141.